Early-Stage trial for rare lung disease halted before completion
NCT ID NCT02363946
First seen Jan 12, 2026 · Last updated May 20, 2026 · Updated 17 times
Summary
This early-stage study tested a new drug called ARC-AAT in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal was to check the drug's safety and how it affects AAT protein levels in the blood. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site 1
Melbourne, Victoria, 3004, Australia
-
Research Site 2
Homburg, Germany
-
Research Site 3
Leiden, 2333ZA, Netherlands
-
Research Site 4
Edgbaston, Birmingham, B15 2WB, United Kingdom
Conditions
Explore the condition pages connected to this study.